Compassionate use programme of irinotecan in colorectal cancer patients in the Netherlands

Netherlands Journal of Medicine

Volumn 61, Issue 7, 2003, Pages 249-256

  ten Bokkel Huinink, W W ^a   van Groeningen, C J ^b   Voest, E E ^c   Peters, W G ^d   Keizer, H J ^e   de Witte, J H ^f  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d CATHARINA HOSPITAL   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Aventis Pharma BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; RALTITREXED; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHOLINERGIC ACTIVITY; CLINICAL PROTOCOL; COLORECTAL CANCER; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG USE; FEBRILE NEUTROPENIA; FEMALE; HEALTH PROGRAM; HUMAN; INFECTION; KAPLAN MEIER METHOD; MALE; METASTASIS; NAUSEA AND VOMITING; NETHERLANDS; NEUTROPENIA; PRACTICE GUIDELINE; REGISTER; SIDE EFFECT; COLORECTAL TUMOR; FOLLOW UP; HEALTH CARE QUALITY; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG APPROVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PROGRAM EVALUATION; TREATMENT OUTCOME;

EID: 0242304211     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Chen Ay, Lie LF. DNA topoisomerases: Essential enzymes and lethal targets. Ann Rev Pharmacol Toxicol 1994;34:191-218.
2. Wiseman LR, Markham A. Irinotecan: A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1996;52:606-23. treatment
3. Cunningham D (ed). Irinotecan (Campto), a new reference in the treatment of colorectal cancer. In: Seminars in Oncology. Philadelphia: W.B. Saunders Company, 1999;26(1, suppl 5).
4. Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM. Irinotecan in the treatment of colorectal cancer: Clinical overview. J Clin Oncol 2001;19:1501-18.
5. Rougier P, Cutsem E van, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-12.
6. Cunningham D, Pyrhönen, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-8.
7. Schmitt C, Blijham G, Jolain B, Rougier P, Cutsem E van. Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure. Anticancer Drugs 1999;10:617-23.
8. Iveson TJ, Hickish T, Schmitt C, Cutsem E van. Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. Eur J Cancer 1999;35:1796-804.
9. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
10. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-14.
11. Rothenberg ML, Eckardt JR, Kuhn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996;14:1128-35.
12. Cutsem E van, Cunningham D, Bokkel Huinink WW ten, et al. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil. Eur J Cancer 1999;35:54-9.
13. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
14. Bonneterre J, Spielman M, Guastalla JP, et al. Efficacy and safety of docetaxel (Taxotere®) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience. Eur J Cancer 1999;35:1431-9.
15. Kruijtzer CMF, Verweij J, Schellens, JHM, et al. Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands. Anticancer Drugs 2000;11:249-55.
16. Freyer G, Rougier P, Bugat R, et al. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5-FU failure. Br J Cancer 2000;83:431-7.